Insider Trading Alert - NATI, HIG And DGX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 7, 2014, 153 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $776.50 to $183,196,515.00.

Highlighted Stocks Traded by Insiders:

National Instruments (NATI) - FREE Research Report

Kodosky Jeffrey L, who is Director at National Instruments, sold 4,000 shares at $27.42 on May 7, 2014. Following this transaction, the Director owned 939,180 shares meaning that the stake was reduced by 0.42% with the 4,000-share transaction.

The shares most recently traded at $27.83, up $0.41, or 1.46% since the insider transaction. Historical insider transactions for National Instruments go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 11,000
  • 24-Week # shares sold: 31,255

The average volume for National Instruments has been 379,000 shares per day over the past 30 days. National Instruments has a market cap of $3.5 billion and is part of the technology sector and computer software & services industry. Shares are down 13.93% year-to-date as of the close of trading on Wednesday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. The stock currently has a dividend yield of 2.19%. The company has a P/E ratio of 42.8. Currently, there is 1 analyst who rates National Instruments a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, premium valuation and relatively poor performance when compared with the S&P 500 during the past year. Get the full National Instruments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hartford Financial Services Group (HIG) - FREE Research Report

Swygert H Patrick, who is Director at Hartford Financial Services Group, sold 11,000 shares at $35.61 on May 7, 2014. Following this transaction, the Director owned 32,601 shares meaning that the stake was reduced by 25.23% with the 11,000-share transaction.

Richardson Julie, who is Director at Hartford Financial Services Group, bought 4,500 shares at $35.40 on May 7, 2014. Following this transaction, the Director owned 4,500 shares meaning that the stake was reduced by 100% with the 4,500-share transaction.

The shares most recently traded at $35.62, up $0.22, or 0.61% since the insider transaction. Historical insider transactions for Hartford Financial Services Group go as follows:

  • 4-Week # shares sold: 21,005
  • 12-Week # shares sold: 21,005
  • 24-Week # shares sold: 21,005

The average volume for Hartford Financial Services Group has been 3.8 million shares per day over the past 30 days. Hartford Financial Services Group has a market cap of $15.7 billion and is part of the financial sector and insurance industry. Shares are down 2.48% year-to-date as of the close of trading on Wednesday.

The Hartford Financial Services Group, Inc., through its subsidiaries, provides insurance and financial services to individual and business customers primarily in the United States and Japan. The stock currently has a dividend yield of 1.72%. The company has a P/E ratio of 18.0. Currently, there are 11 analysts who rate Hartford Financial Services Group a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HIG - FREE

TheStreet Quant Ratings rates Hartford Financial Services Group as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Hartford Financial Services Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Quest Diagnostics (DGX) - FREE Research Report

Guinan Mark, who is Senior Vice President & CFO at Quest Diagnostics, bought 4,000 shares at $55.51 on May 7, 2014. Following this transaction, the Senior Vice President & CFO owned 44,222 shares meaning that the stake was reduced by 9.94% with the 4,000-share transaction.

The shares most recently traded at $57.52, up $2.01, or 3.5% since the insider transaction. Historical insider transactions for Quest Diagnostics go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 778
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 4,465
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 4,465

The average volume for Quest Diagnostics has been 2.4 million shares per day over the past 30 days. Quest Diagnostics has a market cap of $8.0 billion and is part of the health care sector and health services industry. Shares are up 4.41% year-to-date as of the close of trading on Wednesday.

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. The stock currently has a dividend yield of 2.38%. The company has a P/E ratio of 10.5. Currently, there are 2 analysts who rate Quest Diagnostics a buy, 4 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGX - FREE

TheStreet Quant Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

National Instruments Has More Room on the Upside

National Instruments Has More Room on the Upside

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Insiders Are Scooping Up These 5 Stocks Right Now

Insiders Are Scooping Up These 5 Stocks Right Now

Insider Trading Alert - NATI, PCLN And LQ Traded By Insiders

Insider Trading Alert - NATI, PCLN And LQ Traded By Insiders

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales